Posts

Posted on

Isoray’s Cesium-131 Spotlighted in Multiple Presentations at ASTRO

Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Cancers At World’s Premier Radiation Oncology Society 

RICHLAND, Wash., Nov. 24, 2020 (GLOBE NEWSWIRE) — The importance of Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate and brain cancers was underscored in multiple presentations at the ASTRO 2020 annual meeting in Miami, Florida. During the virtual meeting, attendees were able to learn about the increasing body of clinical evidence showing that Cesium-131 has been found to be a valuable option in the treatment of prostate and brain cancer for clinicians and their patients.

Commenting on the presentations, Isoray CEO Lori Woods said, “It is very gratifying that so many Cesium-131 studies made it through review to the meeting proceedings of the world’s leading organization in radiation oncology. A tremendous amount of work goes into each study at these respective institutions, and each illustrates a continued interest in research related to Cesium-131 cancer treatment. We are proud that our leading brachytherapy treatment is at the forefront in bringing important benefits to cancer patients and the medical professionals who care for them.”

Two studies, The Effect of Positive Biopsy Cores on the Prognosis of Patients with Intermediate Risk Prostate Cancer Treated with Cs-131 Prostate Brachytherapy, Smith, Benoit, Beriwal, et al. UPMC, Pittsburgh PA and Report of a Large Cohort of Intermediate-Risk Prostate Cancer Patients Treated with Cs-131 Brachytherapy, Rodriguez-Lopez, Beriwal, Benoit, et al., UPMC Pittsburgh PA, looked at the use of Cesium-131, commercially known as Cesium Blu, in the treatment of intermediate risk prostate cancer. These studies make the case that many intermediate risk prostate cancer patients can be treated successfully with a Cesium-131 implant alone. Importantly, these studies show the excellent outcomes for Cesium-131 patients in this intermediate risk patient group.

Among the presentations that looked at Cesium-131 in the treatment of brain cancer was the study, A Matched Pair Analysis Of Clinical Outcomes After Intracavitary Cesium-131 Brachytherapy Versus Stereotactic Radiosurgery For Resected Brain Metastases, Vanderbilt, Schwartz, et al., Weill Cornell Medical College, NY. In this study, 30 patients with brain metastases underwent surgery and Cesium-131 brachytherapy. These patients were “matched” to 60 patients who underwent treatment of brain metastases with surgery and stereotactic radiosurgery (SRS). The patients who underwent Cesium-131 implantation at surgery as opposed to those who underwent SRS following surgery had lower rates of local recurrence and complications such as radiation necrosis.

Another study, Cs-131 Intracavitary Brachytherapy as an Adjunct to Maximal Safe Resection for Locally Recurrent High-Grade Glioma, Patel, Chen, Dusenbery, et al., Univ Minnesota, Minneapolis, involved the use of GammaTile, powered by Cesium-131 in the treatment of ten patients with brain cancers including some patients with glioblastoma multiforme (GBM). These patients had all been treated with surgery, chemotherapy, and radiation and their cancers had progressed. Nine of the ten patients had failed second line (salvage) therapy as well. The study demonstrated that treatment with Cs-131/GammaTile offers a way to provide therapeutic levels of re-irradiation that begin at the time of surgical placement of the GammaTiles. The successful delivery of high dose radiation with a low rate of complications and no radiation necrosis is very promising in the treatment of these brain malignancies.

Isoray is a medical technology company and innovator in seed brachytherapy. The Company is the world’s only producer of Cesium-131 brachytherapy, commercially known as Cesium Blu, which is powering expanding internal radiation treatment options throughout the body for difficult to treat lung, brain, gynecological, head and neck, pelvic, and colorectal cancers as well as prostate cancer.

About Isoray

Isoray, Inc., through its subsidiary, Isoray Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Safe Harbor Statement

Statements in this news release about Isoray’s future expectations, including whether the studies discussed in this news release will have favorable outcomes in commercial settings, the advantages of Cesium-131 and its delivery systems coupled with surgery, the perception by patients of quality of life outcomes compared to other treatment options, whether demand for and use of Cesium-131 will increase or continue as anticipated and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as whether additional studies are released that support the conclusions of the studies discussed in this news release, whether ongoing patient results are favorable and in line with the conclusions of clinical studies and initial patient results, physician acceptance, training and use of our products, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, changes in laws and regulations applicable to our products, and other risks detailed from time to time in Isoray’s reports filed with the U.S. Securities Exchange Commission. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Contact
Media and Public Relations: Sharon Schultz (302) 539-3747
Investor Relations: Mark Levin (501) 255-1910

Posted on

Banco Macro announces the death of its Chairman Jorge H. Brito

PR Newswire

BUENOS AIRES, Argentina, Nov. 24, 2020 /PRNewswire/ — Banco Macro S.A. (NYSE: BMA; BYMA: BMA) (“Banco Macro” or “BMA” or the “Bank”) 

It is with great sorrow that we inform you of the death of the Chairman of our Board, Mr. Jorge Horacio Brito. We attach a copy of the Press Release issued by the Bank as a consequence of his death.

Pursuant to article 17 of the Bylaws, the office of the Chairman shall be covered by the Vice Chairman, Dr. Delfín J. Ezequiel Carballo. At the first Board meeting to be held, the appointment of a new Vice Chairman and the election, from among the Alternate Directors appointed by the General Shareholder Meeting, of the one who will assume in order to complete the number of regular directors will be discussed.


Buenos Aires, November 20th 2020

It is with great sorrow that Banco Macro announces the death of its founder and Chairman, Mr. Jorge Horacio Brito, who this afternoon suffered an aviation accident in the town of Coronel Moldes, Province of Salta.


Jorge Horacio Brito was born in Buenos Aires in 1952. He married Marcela Carballo and had six children: Milagros, Jorge Pablo, Constanza, Marcos, Santiago and Mateo. He had 12 grandchildren.

We both founded in 1978 Macro Compañía Financiera S.A., a company that was the origin of what we nowadays know as Banco Macro. Brito was also the President of Asociación de Bancos Argentinos between 2003 and 2016. He was as well President of Federación Lationamericana de Bancos from 2012 to 2014.

His enterprising spirit led him to create other businesses such as Inversora Juramento S.A., Frigorífico Bermejo, Cabaña Juramento, Vizora and several companies that employ over 20,000 Argentine workers.

Jorge leaves us at the height of this life. All of us who make Banco Macro everyday shall never forget his example of work, dedication and effort.

Dr. Delfín Jorge Ezequiel Carballo
Vice Chairman of Banco Macro

IR Contact in Buenos Aires:

Jorge Scarinci | Chief Financial Officer
Nicolás A. Torres | Investor Relations
E-mail: [email protected] | Phone: (54 11) 5222 6682

About
Banco Macro S.A (NYSE: BMA; BYMA: BMA) is a universal bank, with focus in low & mid-income individuals and small & mid-sized companies. The Bank started operating in 1985 as non-banking financial institution and today has grown to be the private local bank with the largest branch network in the country.

For futher information access www.macro.com.ar/relaciones-inversores

Cision View original content:http://www.prnewswire.com/news-releases/banco-macro-announces-the-death-of-its-chairman-jorge-h-brito-301179736.html

SOURCE Banco Macro S.A.

Posted on

Oramed Initiates Phase 3 Trial of Oral Insulin

PR Newswire

NEW YORK, Nov, 24, 2020 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened  the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).  The patients were screened at U.S. sites participating in Oramed’s ORA-D-013-1 trial, one of two Phase 3 trials being conducted in accordance with U.S. Food and Drug Administration approved protocols.

Oramed Pharmaceuticals Logo (PRNewsfoto/Oramed Pharmaceuticals Inc)

Both Phase 3 trials, ORA-D-013-1 and ORA-D-013-2, will treat T2D patients who have inadequate glycemic control over a period of 6 to 12 months. The double-blinded, placebo-controlled, multi-center randomized trials will recruit a total of 1,125 patients to evaluate the efficacy and safety of ORMD-0801.  Efficacy data will become available after all patients have completed the first 6-month treatment period.

“ORMD-0801 is the first oral insulin capsule to achieve the requisite efficacy and safety data enabling us to run the world’s first FDA Phase 3 oral insulin trial. Oramed is proud to lead the field in reaching this very significant diabetes treatment milestone,” stated Oramed CEO Nadav Kidron.

About the Study

ORA-D-013-1 is recruiting 675 patients who are currently on 1, 2 or 3 oral glucose-lowering agents through 75 clinical sites throughout the U.S. The primary endpoint of the study is to compare the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by A1c, with a secondary endpoint of assessing the change from baseline in fasting plasma glucose at 26 weeks.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.

For more information, please visit www.oramed.com.

Forward-looking statements:  This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential efficacy, safety and toleration of ORMD-801, the validation of preliminary findings in future trials, the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes or revolutionizing the treatment of diabetes with our products. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to time with the Securities and Exchange Commission.

Company Contact

Estee Yaari

+1-844-9-ORAMED
[email protected] 

Cision View original content:http://www.prnewswire.com/news-releases/oramed-initiates-phase-3-trial-of-oral-insulin-301179301.html

SOURCE Oramed Pharmaceuticals Inc.

Posted on

Quanta Appoints John S. Lipman as President of North America

Quanta Appoints John S. Lipman as President of North America

Alcester, Warwickshire, UK, 24 November 2020: Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British medical technology company developing innovative dialysis products and services, announces the appointment of John S. Lipman as President of North America.

John will lead Quanta’s commercial operations and activities in the United States. He is already working to set up operations and to prepare for commercial launch, which is planned to follow soon after 510(k) clearance is obtained from the FDA for the company’s portable haemodialysis system SC+. He is also joined by Deborah Singer and Michelle Gazella as Head of Chronic Sales and Head of Clinical Support, respectively, bringing more than 40 years’ sales and clinical dialysis experience, with both holding senior positions at Fresenius Medical Care and NxStage.

John has over 25 years of leadership experience, developing and leading pre-launch and commercial companies across the medical device industry. John began working with Quanta as a consultant, and before that was Chief Commercial Officer at NightBalance for four years prior to its acquisition by Philips, where he was responsible for leading the US launch of the Lunoa sleep therapy device. At ApniCure John was Vice President of Marketing & Sales for eight years, where he deployed and expanded a US sales team to launch a new treatment for Obstructive Sleep Apnea. John has also held positions at FoxHollow Technologies and two Johnson & Johnson subsidiaries, LifeScan and Scios. He graduated from California Polytechnical State University and holds an MBA in Marketing from the University of San Francisco.

John E Milad, CEO of Quanta, said:
“I’m delighted that John has joined Quanta’s executive team. He brings a wealth of experience in launching novel medical products and building successful commercial organisations. I look forward to working with him to establish our US operations and bring SC+ to the world’s largest dialysis market.”

Commenting on his appointment, John Lipman said:
“I’m
excited to be leading Quanta’s US business development and commercial activity at such an important time in the company’s development. SC+ represents a unique and disruptive opportunity for the US haemodialysis market, which rarely sees any innovation. In an industry which is notoriously slow to adapt and bring benefits from new technology to patients, Quanta is offering a versatile solution, designed with flexibility and freedom in mind that could revolutionise the way we think about kidney care. I look forward to leading Quanta’s US commercial operations and working together with the senior leadership team to bring SC+ to as many patients and healthcare professionals as we can.”

-ENDS-

For more information about Quanta, please contact:

 

Quanta

John E. Milad,
Chief Executive Officer

 

  

T: +44 (0)1789 400043
E: [email protected]
Consilium Strategic Communications

Amber Fennell / Matthew Neal / Lindsey Neville		 T: +44 (0)203 709 5708
E: [email protected]

About Quanta and SC+

Based in the Midlands of the UK, Quanta is a technology-enabled provider of innovative dialysis products and services. Quanta aims to improve dialysis experiences and help people to live more freely. The lead product SC+ is a small, simple and versatile haemodialysis system designed to provide greater freedom and flexibility in the delivery of life sustaining dialysis treatments — making the therapy manageable to a broad range of users across a wide range of environments.

SC+ is commercially available in the UK, where it has been successfully used to treat patients across a range of care settings, from the ICU and the clinic to the home. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The unobtrusive, simple-to-use and digitally connected design of SC+ is intended to empower more patients to take control of their lives with selfcare and home dialysis. Meanwhile, as a compact, portable and versatile device, SC+ provides flexibility to deliver dialysis across a wide range of use environments and prescriptions.

For more information, please visit our website: quantadt.com.

510(k) Pending. SC+ is not yet available for sale or use in the USA.



Posted on

BOTS Inc. Launches Crypto Bot Software for Crypto Exchanges.

Jacksonville, Florida, Nov. 24, 2020 (GLOBE NEWSWIRE) — BOTS, Inc. (OTC: BTZI) (The “Company”) an emerging innovator of products, technologies and services for the rapidly growing cyber-security, digital robotics automation and A.I. for the manufacturing industry, announced today that together with Bots Marketplace, LLC, have developed a cryptocurrency trading bot that is simple and intuitive for crypto beginners to setup and run.

“The 24/7 opening hours of the crypto market has necessitated the use of trading automation for investors that are involved in trading cryptocurrencies. Understanding this, we created CryptoBOT to help investors automate, run and manage it anytime, anywhere.” – said Paul Rosenberg, CEO of BOTS, Inc.

Using familiar or popular technical indicators such as the Bollinger Band or Relative Strength Index, CryptoBot will be constantly adding more technical indicators. Besides this, CryptoBot allows you to access trade history, individual performances, profit and loss from a top-level overview to a granular level of each bot or trade. You can also select trading pairs, direction, technical indicators to enter or exit and risk management settings in the bot to trade on a connected exchange such as Binance.

For beginners, paper trade functions allow you to test bot trading using real-time data without risking actual cryptocurrencies. You’re able to backtest your strategies to get historical performances with key metrics and indicators that can help forecast future performance or shape expectations.

“We are excited about the launch of CryptoBot. CryptoBot will give many of us who are time-starved the opportunity to trade the cryptomarkets via automated trading bots. Our CryptoBot was already tested on one of the biggest Crypto Exchanges and we are ready to bring our product to other exchanges around the globe. The Company is in the final stage of negotiations to acquire an interest in one of European Crypto Exchanges, where tools like CryptoBot will be used and help traders, at the same time generating substantial revenues for BOTS, Inc.”, concluded Paul Rosenberg, CEO of BOTS, Inc.

About BOTS, Inc.

Headquartered in San Juan, Puerto Rico, BOTS, Inc., a publicly-traded OTC Markets innovator trading under the symbol (BTZI) – is a diversified company developing and servicing blockchain and robotics solutions for its clientele. The Company is committed to driving the innovations needed to shape the future of digital robotic automation management through digital technology and decentralized blockchain solutions. Management is dedicated to the strong growth of Distributed Asset Technology, Cyber Security, and Robotic Process Automation (RPA).

Shareholders, potential investors, and others should note that we announce material events and material financial information to our shareholders and the public using our website and the social media addresses listed below, as well as in our SEC filings, press releases, public conference calls, and webcasts. We also use social media to communicate with our subscribers and the public about our Company, our services, and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage shareholders, the media, and others interested in our Company to review the information we post on the U.S. social media channels listed below. This list may be updated from time to time.

Track BTZI news on Facebook @ https://www.facebook.com/Bots.Bz/

Follow BTZI news on Twitter @Bots_bz http://www.Twitter.com/Bots_bz

Find BTZI news at http://www.bots.bz

Bots, Inc. has been featured in media nationwide, including CNBC, Bloomberg, TheStreet.com.

For more information, visit http://www.bots.bz

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as may be disclosed in the Company’s filings. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release, and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release. Such forward-looking statements are risks that are detailed in the Company’s website and filings.

Contact:

Paul Rosenberg, CEO

[email protected]



Posted on

Maxeon Solar Technologies to Participate at Bank of America 2020 Virtual Renewable Energy Symposium

PR Newswire

SINGAPORE, Nov. 24, 2020 /PRNewswire/ — Maxeon Solar Technologies, Ltd., (NASDAQ:MAXN), a global leader in solar innovation, announced today that its management team will present at Bank of America 2020 Virtual Renewable Energy Symposium on December 3, 2020, at 1:00 PM ET / 10:00 AM PT.

The Company will also host virtual investor meetings throughout the day. Attendance at the conference is by invitation only for clients of Bank of America. Interested investors should contact your Bank of America sales representative to secure a meeting time.

About Maxeon Solar Technologies
Maxeon Solar Technologies Ltd (NASDAQ: MAXN) is Powering Positive Change™. Headquartered in Singapore, Maxeon designs, manufactures and sells SunPower® brand solar panels in more than 100 countries, operating the SunPower brand worldwide except the United States and Canada. The Company is a leader in solar innovation with access to over 900 patents and two best-in-class solar panel product lines. With operations in Africa, Asia, Oceania, Europe and Mexico, Maxeon’s products span the global rooftop and solar power plant markets through a network of more than 1,100 trusted partners and distributors. A pioneer in sustainable solar manufacturing, Maxeon leverages a 35-year history in the solar industry and numerous awards for its technology. For more information about how Maxeon is Powering Positive Change™ visit us at https://www.maxeon.com/, on LinkedIn and on Twitter.

© 2020 Maxeon Solar Technologies, Ltd. All Rights Reserved. MAXEON is a registered trademark of Maxeon Solar Technologies, Ltd. Visit www.maxeon.com/trademarks for more information.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/maxeon-solar-technologies-to-participate-at-bank-of-america-2020-virtual-renewable-energy-symposium-301179576.html

SOURCE Maxeon Solar Technologies, Ltd.

Posted on

Home Searches in Cities Up 200% From Last Year, Reflecting Renewed Interest in Urban Areas After Pandemic-Driven Drop

The uptick in urban home searches closely trails a 235% increase in searches for homes in rural areas

Home prices were up by double digits in both neighborhood types, reflecting both continued interest in rural life and optimism about the return of city life as the pandemic persists

PR Newswire

SEATTLE, Nov. 24, 2020 /PRNewswire/ — (NASDAQ: RDFN) — Pageviews of homes in rural areas increased 235% year over year in October, a large increase but still a deceleration from a 273% peak in August, according to a new report from Redfin (www.redfin.com), the technology-powered real estate brokerage. The story is similar in small towns, where pageviews rose 218% year over year in October—a major increase, but less of a boom than the 233% peak in September.

Meanwhile, October represented a sign of renewed interest in urban areas with the biggest annual increase in pageviews since it stagnated in March and April. Pageviews of homes in large metro areas–which includes cities and their surrounding suburbs–rose 200% year over year in October. Pageviews of homes in large metro areas, rural areas and small towns are converging toward similar year-over-year increases as Redfin.com searches in rural areas and small towns start to settle and cities pick up steam.

“Rural areas and small towns remain desirable—especially for families who need space to accommodate remote work as the pandemic persists—but record-low mortgage rates are motivating people to search in cities, too,” said Redfin chief economist Daryl Fairweather. “Many buyers are crossing their fingers that restaurants, bars and shops may be bustling again in the next year or so, and they’re looking to invest in the eventual resurgence of cities.”

Home prices up 18% year over year in rural areas and nearly 16% in urban areas

The median home-sale price in rural areas nationwide rose 18.3% year over year to $300,000 in the four weeks ending November 8, the biggest increase and highest median sale price since Redfin started tracking this data in the beginning of 2017. Prices also posted record growth in suburban and urban areas: Suburban areas saw a 14.3% year over year increase to roughly $331,500, while the median sale price in urban areas rose 15.6% to $289,000.

The housing market data in the report divides rural, suburban and urban based on categories from the U.S. Department of Housing and Urban Development, which built a model to describe neighborhood types based on responses to the 2017 American Housing Survey. Note that the categories in this section are different from the categories in the section on Redfin.com pageviews, which divides areas into large metro areas, small towns and rural areas.

Home-price growth stalled in rural, suburban and urban areas in May and June as a result of initial uncertainty stemming from the coronavirus pandemic. Price growth declined 3.5% year over year in May in urban areas, the only neighborhood type where prices dropped. Prices increased 1.6% year over year in the suburbs and 3.2% in rural neighborhoods in May, the month when price growth bottomed out. 

The remote work and homeschooling that have come with the pandemic led to a surge in interest in less densely populated areas over the summer, with demand for rural and suburban areas outpacing demand for urban areas. Though the housing market is still hottest in rural neighborhoods, urban areas are making a comeback.

“While life in the city has changed during the pandemic, with empty sidewalks and boarded-up storefronts becoming the norm, some buyers are looking long-term and realizing it’s possible to buy a condo for a 2017 price without competition,” said Jessie Culbert Boucher, a Redfin real estate agent in Seattle. “If they hold onto it for five years, they’ll likely ride out the current downturn, make money and enjoy the return of vibrant city life.”

Total home sales were up 11.4% year over year in rural areas during the four weeks ending November 8, and they were up 15.4% and 9.3% in suburban and urban neighborhoods. Home sales in all three neighborhood types dropped drastically with the onset of the pandemic in the spring. Rural sales were the first to recover, followed closely by suburban and urban areas.

Pending sales, a more current housing market indicator, jumped significantly in all three neighborhood types in October. Pending sales were up 37.4% year over year in rural areas in the four weeks ending November 8, and they were up 36% and 26.1% in suburban areas and urban areas, respectively.

The housing supply shortage is more severe in rural and suburban areas than urban areas, with the number of homes for sale down 40.9% and 31.9% year over year in the four weeks ending November 8, respectively. In urban areas, supply dropped 14.5% year over year. The fact that home supply dropped so significantly in rural and suburban areas reflects intense homebuyer interest in homes outside city centers. Supply is also down by double digits in urban areas, though it’s worth noting that home supply was up 70% year over year in the city of San Francisco in October.


National Housing Market Summary, Four Weeks Ending November 8


Rural areas


Suburban areas


Urban areas

Median sale price

$300,000

$330,500

$289,000

Median sale price, YoY

18.3%

14.3%

15.6%

Median price per square foot

$149

$167

$184

Median price per square foot, YoY

13.1%

11.6%

14.2%

Home sales, YoY

11.4%

15.4%

9.3%

Pending sales, YoY

37.4%

36%

26.1%

Number of homes for sale, YoY

-40.9%

-31.9%

-14.5%

New listings, YoY

8.8%

13.4%

13.7%

To read the full report, including graphs, please visit: https://www.redfin.com/news/home-price-increase-rural-urban-searches.

About Redfin
Redfin (www.redfin.com) is a technology-powered residential real estate company, redefining real estate in the consumer’s favor in a commission-driven industry. We do this by integrating every step of the home buying and selling process and pairing our own agents with our own technology, creating a service that is faster, better and costs less. We offer brokerage, iBuying, mortgage, and title services, and we also run the country’s #1 real estate brokerage search site, offering a host of online tools to consumers, including the Redfin Estimate. We represent people buying and selling homes in over 90 markets in the United States and Canada. Since our launch in 2006, we have saved our customers over $800 million and we’ve helped them buy or sell more than 235,000 homes worth more than $115 billion.

For more information or to contact a local Redfin real estate agent, visit www.redfin.com. To learn about housing market trends and download data, visit the Redfin Data Center. To be added to Redfin’s press release distribution list, email [email protected]. To view Redfin’s press center, click here.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/home-searches-in-cities-up-200-from-last-year-reflecting-renewed-interest-in-urban-areas-after-pandemic-driven-drop-301179528.html

SOURCE Redfin

Posted on

United Health Products Announces Leadership Changes

United Health Products Announces Leadership Changes

HENDERSON, Nev,–(BUSINESS WIRE)–
United Health Products, Inc. (OTC: UEEC), (“UHP” or the “company”), developer, manufacturer and marketer of HemoStyp®, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today announced changes to its senior management team and its Board of Directors.

Douglas Beplate, co-founder of the company and currently Chief Executive Officer and Chairman of the Board of Directors, will be retiring from the day to day management role and will continue as the Chairman. Brian Thom will assume the role of Chief Executive Officer effective December 1, 2020 and then join the Board of Directors on January 1, 2021.

Mr. Thom has been working closely with UHP since 2018 as a consultant and financial advisor. He brings over 20 years of corporate finance experience and a successful track record of helping fast growing companies across a broad range of industries to raise capital and create shareholder value. Over the course of his career he spent a decade with JPMorgan’s global Mergers and Acquisitions group and five years leading the Americas Corporate Finance group with Société Générale, a multi-national European investment bank, among other entrepreneurial pursuits. During this time, Mr. Thom played a major role in over 60 M&A and equity placement transactions with an aggregate transaction value in excess of $200 billion.

Mr. Beplate commented: “Brian has spent the past two years working with me and the management team and has consequently developed a deep understanding of UHP’s technology and its potential applications across several attractive markets. He has mapped out a clear strategy to transition from our R&D focus to a commercialization phase and I look forward to working closely with Brian to maximize our company’s value for an eventual sale or merger at the appropriate time.”

Concurrent with this change, Nate Knight, UHP’s Chief Financial Officer and a Director, will be retiring after ten years with the company. Kris Heaton will assume the role of Vice President, Finance and serve as principal financial officer. Kris is a CPA who has been working with the company for several years, assisting in preparation of financial statements and SEC filings, and is familiar with UHP’s financial circumstances and growth objectives. Kris’ accounting and financial expertise will serve UHP well as the company ramps up commercial business operations.

Doug Beplate commented: “Nate has been instrumental in securing the financial resources necessary for the company to advance its R&D and FDA application activities. He leaves the company in good shape and we thank him for his dedication to UHP and its shareholders.”

Upon Mr. Knight’s retirement from the Board of Directors, Lou Schiliro, UHP’s Chief Operating Officer, will be appointed to the Board as a Director.

These leadership changes bring the talent, experience and energy that are necessary to successfully guide the company forward. In anticipation of a successful Class III PMA approval, the management team will pursue a full range of commercial, strategic and capital markets initiatives to facilitate growth of the business and create shareholder value.

About United Health Products — United Health Products develops patented wound care technology; manufactures and markets hemostatic products for the healthcare and wound care sectors. The company’s main product, HemoStyp is an all-natural Neutralized Oxidized Regenerated Cellulose product designed to control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and consumer markets.

For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com.

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company contact:

United Health Products, Inc.

877-358-3444

IR Contact:

Philippe Niemetz

212-344-6464

[email protected]

KEYWORDS: Nevada United States North America

INDUSTRY KEYWORDS: Health Medical Devices Surgery Other Health Dental General Health Veterinary

MEDIA:

Posted on

VirTra Announces Winners of the Force Science Scholarship Award

TEMPE, Ariz., Nov. 24, 2020 (GLOBE NEWSWIRE) — VirTra, Inc. (NASDAQ: VTSI), a global provider of training simulators for the law enforcement, military, educational, and commercial markets, today announced the recipients of the VirTra and Force Science Scholarship Award. This award, which was created from a partnership between VirTra and the Force Science Institute, allows twelve outstanding peace officers around the country to earn a scholarship to a five-day Force Science Analyst Certification Course in 2021.

The peace officers chosen were from:

  • Ames Police Department, Ames, IA
  • Aurora Police Department, Aurora, IL
  • Colorado State Park & Wildlife, Orchard, CO
  • Covington Division of Police, Covington City, VA
  • Local Police Curriculum Development & Training Unit, NY
  • Liberty County Sheriff’s Office, Bristol, FL
  • Military Ocean Terminal Concord Police, Concord, CA
  • New Carrollton Police Department, New Carrollton, MD
  • Perrysburg Township Police Department, Perrysburg, GA
  • Portland Police Bureau, Portland, OR
  • Rockdale County Sheriff’s Office, Conyers, GA
  • Santa Barbara County Sheriff’s Department, Santa Barbara, CA

VirTra and the Force Science Institute are furthering research-based and science-backed training that is crucial to better educating law enforcement officers and better preparing them to handle the individual needs of their communities. The course is taught by world-renowned instructors and is designed to provide officers with the necessary tools to help improve their knowledge base and grow their careers.

“This announcement arrives at the perfect time to wish all of our first responders – both law enforcement and military – a wonderful Thanksgiving,” said Jason Mulcahy, general manager of VirTra. “Every day, we are thankful to those who put their lives on the line to keep our communities and our country safe, and it is our hope that the recipients of this scholarship will be able to do so more effectively.”

The courses will be taught in 12 different cities across the country. The winners listed above, whose $1,650 course fee will be paid in full by VirTra, may choose from any course at the date and location most convenient for them. Attendees will also have an opportunity to earn a Force Science Analyst Certification, which demonstrates their ability to recognize the factors that impact human behavior in use-of-force encounters.

About VirTra

VirTra (NASDAQ: VTSI) is a global provider of judgmental use of force training simulators, firearms training simulators and driving simulators for the law enforcement, military, educational and commercial markets. The company’s patented technologies, software, and scenarios provide intense training for de-escalation, judgmental use-of-force, marksmanship and related training that mimics real-world situations. VirTra’s mission is to save and improve lives worldwide through practical and highly effective virtual reality and simulator technology. Learn more about the company at www.VirTra.com.

About
the
Force Science Institute

The Force Science Institute is dedicated to promoting the value of knowledge through empirical research in behavioral science and human dynamics. Force Science develops and disseminates high quality scientifically grounded education, training, and consultation to support fact-based investigations, inform decision processes, enhance public safety, and improve peace officer performance in critical situations. Learn more at www.forcescience.org.

Investor Relations Contact:
Matt Glover or Charlie Schumacher
[email protected]
949-574-3860



Posted on

Finding JOYY In All the Right Places: Invest in Infusive Asset Management’s Compounding Global Equities ETF (NYSE: JOYY)

– Not to Muddy the Waters, but for investors seeking Joyy, consider Infusive Asset Management’s Compounding Global Equities ETF (NYSE: JOYY)

– Infusive’s investment strategy targets consumer desires of real humans and analyzes actual purchasing trends

PR Newswire

LONDON, Nov. 24, 2020 /PRNewswire/ — Infusive Asset Management – investing in brands that people know, love and buy into again and again – is an investment firm rooted in long-term appreciation and consistent growth, managed by industry professionals who monitor for consumer-focused companies that elicit joy and happiness.

But not all joy is created equal. Whereas Infusive’s JOYY is based on thorough, reality-based research that’s been featured in the likes of Bloomberg, Barron’s, CNN and Business Insider, unsuspecting investors may discover some forms of Joyy that haven’t received such positive coverage. Specifically, Infusive’s ETF (NYSE: JOYY) and YY Inc. ([NASDAQ] JOYY) have the same ticker symbol but absolutely nothing to do with each other.

Infusive’s portfolio consists of a carefully vetted list of public companies who generate revenue from goods and services that appeal to consumer driven desires and impulses. Infusive’s investment philosophy, rooted in their Consumer Alpha investing approach, is based on human tendencies to seek out happiness through purchases that enhance beauty, indulgence, entertainment, status, health, convenience, and other innate consumer inclinations.

Infusive’s investment strategy is embedded in long-term appreciation and consistent growth. The company also touts a risk overlay which works to minimize short-term market volatility to help beat market averages and deliver consistent returns – even in times of unpredictability.

Andrea Ruggeri, Chief Executive Officer of Infusive said, “Infusive is dedicated to identifying and exploring consumer brands that offer stable investments based on purchasing behavior and people’s desire to seek out companies and products that elicit real-world joy or happiness. Our ETF’s ticker symbol NYSE: JOYY is a truly fitting representation of our investment strategy.”

“One of Infusive’s greatest asset is our ability to find and understand the JOYY that drives consumer demand. I’d like to welcome any Joyy seeking individuals to take a minute to learn a bit about us and find real reasons to be joyful despite what’s being featured in other news,” he added.

About Infusive

Infusive Asset Management is a New York / London based investment manager expert in human behaviour. It focuses on global brands that people are emotionally connected to and invested in. Infusive™ harnesses it’s Consumer AlphaTM research and investment framework to locate the most rewarding investments in the space. The companies they research sell products that provide happiness to consumers and tend to be characterized by stable revenue streams reflecting consumers’ repeat purchase of their products. Infusive Consumer Alpha investment strategy is accessible through its Consumer AlphaTM Global Leaders Fund (UCITS) and the Infusive Compounding Global Equities ETF (NYSE: JOYY).

Disclaimers
The Infusive Global Compounding Equities ETF (“JOYY ETF”) is not actively managed, and the Advisor generally does not attempt to take defensive positions under any market conditions, including declining markets. The JOYY ETF may be susceptible to an increased risk of loss, including losses due to adverse events that affect the JOYY ETF’s investments more than the market as a whole, to the extent that the JOYY ETF’s investments are concentrated in the securities of a particular issuer or issuers, country, group of countries, region, market, industry, group of industries, sector or asset class. There is no guarantee that the JOYY ETF will achieve a high degree of correlation to the Underlying Index and therefore achieve its investment objective. Market disruptions and regulatory restrictions could have an adverse effect on the JOYY ETF’s ability its exposure to the required levels in order to tracking the Underlying Index. The JOYY ETF is new with limited operating history. Exchange-Traded Funds (ETFs) trade like stocks, are subject to investment risk, and will fluctuate in market value. Unlike mutual funds, ETF shares are not individually redeemable directly with the JOYY ETF, and are bought and sold on secondary market at market price, which may be higher or lower than the ETF’s net asset value (NAV). Transactions in shares of ETFs will result in brokerage commissions, which will reduce returns. You cannot invest directly in an Index.

The Infusive Global Compounding Equities ETF is distributed by ALPS Distributors, Inc.

As of 9/30/2020, Infusive ETF with NYSE ticker JOYY did not hold any shares of YY Inc., with Nasdaq ticker JOYY.

Investors should carefully consider the investment objective, risks, charges, and expenses of the JOYY ETF before investing. To obtain a prospectus containing this and other important information, please visit https://www.infusive.com/holdings/ to view or download a prospectus. Read the prospectus carefully before investing.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/finding-joyy-in-all-the-right-places-invest-in-infusive-asset-managements-compounding-global-equities-etf-nyse-joyy-301179289.html

SOURCE Infusive Asset Management